12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

KD020: Phase Ib/IIa started

Kadmon began a Phase Ib/IIa trial evaluating KD020 in about 200 patients.

Kadmon Corp. LLC, New York, N.Y.
Product:

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >